ESC HOT LINE
EuropeanHeartJournal(2015)36,158–169
doi:10.1093/eurheartj/ehu339 Arrhythmia/electrophysiology
EuroEco (European Health Economic Trial on
Home Monitoring in ICD Patients): a provider
perspective in five European countries on costs and
net financial impact of follow-up with or without
remote monitoring
Hein Heidbuchel1*, Gerd Hindricks2, Paul Broadhurst3, Lieselot Van Erven4,
Ignacio Fernandez-Lozano5, Maximo Rivero-Ayerza6, Klaus Malinowski7,
AndreaMarek8, Rafael F. RomeroGarrido9, Steffen Lo¨scher10, Ian Beeton11,
EnriqueGarcia12, Stephen Cross13, Johan Vijgen1, Ulla-Maija Koivisto14,
Rafael Peinado15, Antje Smala16, and Lieven Annemans17
1HeartCenter,JessaZiekenhuis,Hasselt,Belgium;2HeartCenterLeipzig,Leipzig,Germany;3AberdeenRoyalInfirmary,Aberdeen,UK;4LeidenUniversityMedicalCenter,Leiden,The
Netherlands;5UniversityHospitalPuertadeHierroMajadahonda,Madrid,Spain;6HospitalOost-Limburg(ZOL),Genk,Belgium;7HeliosKlinikum,Aue,Germany;8Charite-Campus
Mitte(CCM),Berlin,Germany;9HospitalUniversitarioNuestraSen˜oradelaCandelaria(HUNSC),St.Cruz,Tenerife;10KlinikumStGeorg,Leipzig,Germany;11St.PetersHospital,
Chertsey,UK;12CentroHospitalarioUniversitarioVigo,Vigo,Spain;13RaigmoreHospital,Inverness,UK;14UniversitalHospitalofOulu,Oulu,Finland;15HospitalUniversitarioLaPaz,La
Paz,Spain;16BIOTRONIKSE&Co.KG,Berlin,Germany;and17GhentUniversity,Ghent,Belgium
Received7July2014;revised20July2014;accepted28July2014;onlinepublish-ahead-of-print1September2014
Seepage143fortheeditorialcommentonthisarticle(doi:10.1093/eurheartj/ehu372)
Aim Remotefollow-up(FU)ofimplantablecardiacdefibrillators(ICDs)allowsforfewerin-officevisitsincombinationwith
earlier detection of relevant findings. Its implementation requires investment and reorganization of care. Providers
(physiciansorhospitals)areunsureaboutthefinancialimpact.Theprimaryend-pointofthisrandomizedprospective
multicentrehealtheconomictrialwasthetotalFU-relatedcostforproviders,comparingHomeMonitoringfacilitated
FU(HMON)toregularin-officeFU(HMOFF)duringthefirst2yearsafterICDimplantation.Alsothenetfinancial
impact on providers (taking national reimbursement into account) and costs from a healthcare payer perspective
wereevaluated.
.....................................................................................................................................................................................
Methods Atotalof312patientswithVVI-orDDD-ICDimplantsfrom17centresinsixEUcountrieswererandomisedtoHMON
andresults orOFF,ofwhich303wereeligiblefordataanalysis.Forallcontacts(in-office,calendar-oralert-triggeredweb-based
review, discussions, calls) time-expenditure was tracked. Country-specific cost parameters were used to convert
resourceuseintomonetaryvalues.RemoteFUequipmentitselfwasnotincludedinthecostcalculations.Givenonly
twopatientsfromFinland(oneineachgroup)amonetaryvaluationanalysiswasnotperformedforFinland.Average
agewas62.4+13.1years,81%weremale,39%receivedaDDDsystem,and51%hadaprophylacticICD.Resource
usewithHMONwasclearlydifferent:lessFUvisits(3.79+1.67vs.5.53+2.32;P,0.001)despiteasmallincrease
of unscheduled visits (0.95+1.50 vs. 0.62+1.25; P,0.005), more non-office-based contacts (1.95+3.29 vs.
1.01+2.64;P,0.001),moreInternetsessions(11.02+15.28vs.0.06+0.31;P,0.001)andmorein-clinicdiscus-
sions(1.84+4.20vs.1.28+2.92;P,0.03),butwithnumericallyfewerhospitalizations(0.67+1.18vs.0.85+1.43,
P¼0.23) and shorter length-of-stay (6.31+15.5 vs. 8.26+18.6; P¼0.27), although not significant. For the
wholestudypopulation,thetotalFUcostforproviderswasnotdifferentforHMONvs.OFF[mean(95%CI):E204
*Correspondingauthor.Tel:+3216344248,Fax:+3216344240,Email:heinheid@gmail.com
&TheAuthor2014.PublishedbyOxfordUniversityPressonbehalfoftheEuropeanSocietyofCardiology.
ThisisanOpenAccessarticledistributedunderthetermsoftheCreativeCommonsAttributionNon-CommercialLicense(http://creativecommons.org/licenses/by-nc/4.0/),whichpermits
non-commercialre-use,distribution,andreproductioninanymedium,providedtheoriginalworkisproperlycited.Forcommercialre-use,pleasecontactjournals.permissions@oup.com
EuroEco,HealthEconomicTrialonhomemonitoring 159
(169–238)vs.E213(182–243);rangefordifference(E236to54),NS].Fromapayerperspective,FU-relatedcosts
weresimilarwhilethetotalcostperpatient(includingotherphysicianvisits,examinations,andhospitalizations)wasnu-
merically(butnotsignificantly)lower.Therewasnodifferenceinthenetfinancialimpactonproviders[profitofE408
(327–489)vs.E400(345–455);rangefordifference(E2104to88),NS],buttherewasheterogeneityamongcountries,
withlessprofitforprovidersintheabsenceofspecificremoteFUreimbursement(Belgium,Spain,andtheNetherlands)
andmaintainedorincreasedprofitincaseswheresuchreimbursementexists(GermanyandUK).Qualityoflife(SF-36)
wasnotdifferent.
.....................................................................................................................................................................................
Conclusion Forallthepatientsasawhole,FU-relatedcostsforprovidersarenotdifferentforremoteFUvs.purelyin-officeFU,
despitereorganizedcare.However,disparityintheimpactonproviderbudgetamongdifferentcountriesillustrates
theneedforproperreimbursementtoensureeffectiveremoteFUimplementation.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
Keywords Implantablecardioverterdefibrillator † Remotemonitoring † Devices † Follow-up † Healtheconomics
Introduction impactontheproviders’netclinicalincomeforFU,andthecosts
forICDFUwithorwithoutremotemonitoringfromahealthcare
Over the last years remote monitoring of implanted devices like payerperspective.Furthersecondaryend-pointsweretherateof
implantable defibrillators (ICD) has been introduced. All stake- in-office FU visits with relevant findings and patient-reported
holdersseepotentialbenefits:physiciansandhospitals(the‘provi- quality-of-lifeassessedbytheSF-36questionnaire.
ders’) may optimize performance by reducing the number of
in-hospital visits, while specialist nurses and/or technicians can
Methods
filteralertsfromtheremotesystem,hencepossiblysavingphysician
time.1 For patients, the technology provides a more continuous
Studydesign
follow-up (FU) and saves time for visits to outpatient clinics that
oftendonotresultinspecificactions.2,3Manystudieshaveshown TheEuropeanHealthEconomicTrialonHMinICDTherapywasaran-
domized,non-blinded,parallel-designtrialinwhich17centresfromsix
thatremotetechnologyresultsinpatientcarethatisnon-inferior
Europeancountries (Belgium 3 centres, Finland 1, Germany 4, UK 3,
toclassicalFUwithin-officevisits.1,4–8Especiallydailyremotemon-
Spain4,TheNetherlands1)participated.Tobeenrolled,patientshad
itoringresultsinearlierdetectionofdeviceandpatient-relatedpro-
to meet the standard indication for a new or replacement VVI- or
blems which translate into earlier clinical decision-making, less
DDD-ICDenabledwithHMtechnologycapableofelectrogramtrans-
inappropriate shocks and improved device longevity.7–9 The mission(BiotronikICDsmodelsLumos,n¼3,orLumax,allothers).
CONNECTtrialalsoshowedasignificantreductioninthelength Therewerenofurtherclinicalin-orexclusioncriteriaexceptage≥18
of cardiovascular hospitalizations9 and the IN-TIME trial even years.ACRT-cohortwasstartedasanextensionandisstillenrolling.
showed a mortality benefit in ICD patients with heart failure.10 Patients were enrolled prior to ICD implantation, after which they
Sometrialshavelookedassecondaryend-pointsatthecostimpact wererandomized1:1toreceiveregularin-officeFUvisits(HMOFF
fromtheperspectiveofthehealthcarepayer.6,11Thereisdataindi- group) or a HM facilitated FU regime (HM ON group) for the next
2years.Threein-officeFUsweremandatoryforallthepatients(within
catingthathealthcarepayersmayhaveadominantstrategyoption
6 weeks after discharge, 12+1 and 24+2 months after discharge)
withremoteICDmonitoring,sincecostsmaybereducedandout-
(seeFigure1).Furtherin-officeFUvisitswerescheduledaccordingto
comesimprovedwithremoteFU.
eachcentre’sindividualroutinefortheHMOFFpatientsonly.Unsched-
Whileinvestigatorshaveevaluatedthetimeneededfromphysi-
uledin-officeFUvisitsinitiatedbythephysicianorthepatientcouldoccur
ciansandnurses/techniciansforremotemonitoring,12–14aformal
inbothpatientgroupsatanytimeduringthestudy.Patientsrandomized
costanalysisfromtheproviderviewpointhasneverbeenperformed. toHMONwereundercontinuous,automaticremotemonitoringduring
Nevertheless, the net financial impact on providers will influence theentirestudy.ThefrequencyofHMdataanalysisandtheresponseto
theirwillingnesstochangecaremodelsfromreimbursedin-hospital HMalertswaslefttotheinvestigators’discretion.
visitstoremoteevaluation,especiallywhenthelatterisnotreim- The study was conducted in accordance with the Declaration of
bursed and given the investments needed to train nurses and Helsinki.TheprotocolwasapprovedbytheEthicsCommitteesofallpar-
employthosefortheFUactivities.15Industryhastoprovideaddition- ticipatinginstitutionsandthetrialwasregisteredwithclinicaltrials.gov
under identifier NCT00776087. All the patients gave their written
alhardware(transmitters),setupinfrastructure(servers)andtake
informedconsenttoparticipateinthetrial.
care of communication costs, which are not covered separately
fromthedeviceprice.Ifallstakeholderswanttostimulateareorgan-
Medicalandresourceusedatacollection
izationofFUforICDpatientstowardsremotemonitoring,theyneed
Allmedicalcontactsofthepatientswererecordedoverthecourseofthe
toknowitscoststructuretoensureproperfinancingforthefuture.
trialfrompaperorelectroniccharts,includingcontactswiththeprovider
Therefore,theprimaryobjectiveofthisEuroEcotrialwastoevaluate
(in-office,plannedorweb-baseddatareviewfollowingalerts,internaldis-
theimpactonthecostforproviderswhenrelyingonHomeMonitor-
cussions, phone calls) as well as visits to other physicians, additional
ing(HM)-basedFUcomparedwithclassicalFUwithonlyin-office
medicalexaminations,andhospitaladmissions.Allactionstakenwere
visits.Sincereimbursementsystemsareveryheterogeneousindiffer- evaluatedforclinicalrelevancebyaninvestigatorblindedtogroupassign-
ent European countries, secondary objectives were to study the ment and based on pre-specified criteria. A second blinded scientist
160 H.Heidbucheletal.
Figure1 Flowofpatientsbetweenenrolmentandendoffollow-up.Seetextforfurtherdetails.Patientswith‘irregularearlytermination’didnot
terminatethestudywithapre-specifiedfinal24-monthfollow-up.However,foronepatientintheHMOFFgroupandthreepatientsintheHMON
group,datawereavailablebeyond22monthsafterimplantdischarge.HM,HomeMonitoring;FU,follow-up;HTX,hearttransplantation;‘upgrade’,
implantablecardiacdefibrillatorupgradetoacardiacresynchronizationdevice.
double-checkedthedecisions.Patientsself-reportedtheirquality-of-life (typeofstaffandduration)wastracked,oftenusingpurpose-builtelec-
usingSF-36atrandomization,andafter1and2yearsofFU. tronic documentation tools (web-based time-tracking software that
Forallprovidercontacts(includinginternaldiscussionsbetweenstaff wasactivatedattheopeningandclosureofanycontact;dedicatedchron-
members,phonecalls,andunscheduledvisits),stafftimeconsumption ometers;automaticloggingofcallsonmobilephonesofnursesand/or
EuroEco,HealthEconomicTrialonhomemonitoring 161
physicians).Allstudypersonnelwastrainedtologtimeoncontactsfor For the analysis of the SF-36v2 questionnaires, Health Outcomes
EuroEcopatients.Datawerelaterenteredinpaper-basedcasereport Scoring Software 4.5 (QualityMetric Incorporated, Lincoln, RI, USA)
forms. The hospital charts of the patients were clearly labelled to wasused.Thereby,rawdataoftheSF36-itemsweretransformedinto
remindstudypersonnelaboutthepatient’sinclusioninthetrialandthe eightsubscoresbyusingtheQualityMetric’sMissingScoreEstimator.
needfortimelogging. These variables were transformed in subscores based on 2009 US
norms, from which the mental health sum-score MCS and physical
healthsum-score(PCS)werecalculated.Inadditiontobothsum-scores,
Monetaryvaluation:healthcarecosts
subscoresbeforenorm-basingwereanalysedwithrespecttoanydiffer-
Costanalysiswasconductedfromtheproviderperspectiveandfromthe encebetweenHMONvs.HMOFFtoruleoutanybiascausedbyusing
healthcarepayerperspective.Providernetincomewascalculatedasthe thestandardUSnormforEuropeanpatients.Forthepurposeofcom-
differencebetweenpayerreimbursementforFUservicesandprovider parative analysis, the non-parametric Mann–Whitney U test was
costrelatedtoFU.Country-specifictariffsandstaffcostswereusedto appliedhereaswell.
convertmeasuredresourceuseintomonetaryvaluesandcalculatethe Costperpatientwasdescribedbymean,standarddeviation,median,
costsperpatient.Non-medicalcosts(overhead)werederivedfromcal- minimum, maximum, and 95% confidence intervals (CI). Confidence
culated staff time and estimated office space, based on nationally intervals were generated using the non-parametric bootstrapping
accepted percentages. Given only two patients from Finland (one in method with 1000 replicates. If the 95% CI for difference excluded
each group) cost calculations were not performed for this country. zero,thecostdifferenceswasconsideredstatisticallysignificantatthe
Remotemonitoringequipmentitselfwasnotincludedinthecostcalcula- P¼0.05 level. The data were bootstrapped by study arm to ensure
tionsbecauseofitsarbitraryvalues;weratheroptedforananalysisthat the treatment balance remained constant. Costs were calculated for
shows payers possible margins for reimbursement of the technology thewholemixofpatientsasenrolledinthestudy,andalsobycountry
basedontheiroverallbudgetimpact. basedonitscorrespondinggroupingofresourceutilizationdata(see
Payercostswerebasedondiagnosis-relatedgroupstariffs,nationalor above).
regionalfee-for-servicetariffs,publicgeneralhospitaltariffs,orpublica- Pre-specifiedsubgroupswereevaluatedinamultivariateanalysisfor
tionsattheendof2013.Ifgeographicdifferenceswerenotedwithina their impact on provider and payer costs. These subgroups were
singlecountry,amid-pointestimateofthevariousobservedtariffswas single-vs.dual-chamberICD,primaryvs.secondarypreventionindica-
taken.AllcostswereexpressedinEuro(E).Ifnotavailable,2013costs tion,NYHAclass≤IIand≥III,andagebelowvs.abovemedian,apart
wereestimatedbyapplyinganappropriateinflationfactortoprevious fromHMONvs.OFFandcountry.
yearcostsusingthecountry-specificconsumerpriceindex.
Astratifiedexploratoryanalysiscomparingcountrieswithdifferent
Results
reimbursement systems was pre-specified as a secondary end-point.
Thechallengesofanappropriatemethodforanalysinghealthcaredata
fromdifferentjurisdictionshavebeendiscussedbyothers.16–18Arecom- Patientcharacteristicsandstudyexecution
mendedmethodtocalculatethecostsforagivencountryistoconsider
Of312patientsenrolledbetweenJuly2008andJuly2011,303were
theresourceuseofallpatientsinthesampleandthenapplytothese
eligibleforFUdataanalysisandconstitutedtheactualsamplesize
resourcescostdataforthatcountry.However,thismethodcanonly
(159randomizedtoHMON,144randomizedtoHMOFF)since
be applied if resource use is homogeneous within the sample. Key
nine patientsterminatedthe studyprematurely without providing
resource utilization data from the different countries (number of FU
anydataafterrandomization(BEn¼87,FIn¼2,DEn¼88,UK
visits,timespentbyhealthcareworkers,hospitalizationdata)werethere-
foreanalysedusinggeneralizedlinearmodellingtoverifywhetherthey
n¼47,ESn¼54,NLn¼25).Thebaselinecharacteristicsofthe
weresufficientlyhomogeneoustobeavalidbasisforcalculatingcountry- twostudygroupsweresimilar(Table1)exceptfortherateofpatients
specificcosts.Overallheterogeneityinresourceusewasdetected.Two withaprimaryprophylacticindication,whichwashigherintheHM
sets of countries with homogeneous utilization (mainly based on the ONgroup.
numberofFUvisitstotheprovidercentre)wereidentified,comprising Six patients crossed over from HM OFF to ON for medical
Belgium, The Netherlands, and the UK in one group and Finland, reasons.Infourcases,theinvestigatorstoppedstudyparticipation
Germany,andSpaininanother.
forthesepatients,whiletheothertwowereanalysedaccordingto
theintention-to-treatprinciple.Atotalof61patients(20.1%)termi-
Statisticalmethods natedthestudybeforethepre-specified24-monthFUvisit,mainly
duetodeathorotherclinicalend-points(Figure1).Theremaining
Thesamplesizeestimatewasbasedonananticipatedreductionoftotal
242patientsterminatedthestudyasplannedatthe24-monthFU.
timeneededforFUby14.5minover2years,derivedfromearlynon-
The median FU duration after randomization was 24.0 months
randomizedtrialsandinvestigatordatabases.Foratwo-sidedsignificance
levelof5%todetectthisdifferenceandapowerof80%,312patients (IQR: 23.1–24.5) in those patients and 11.9months (IQR: 5.1–
wereneeded.Aheadofdatabaseclosure,statisticalanalysisplanswere 19.4) in patients with early termination, without differences
developedfortheclinicalandthehealtheconomicevaluation,respect- betweenstudygroups.
ively,definingallanalyticaldetails.TheSASsoftware(SASInstitute,Inc.,
USA)wasusedtoevaluateutilizationdataandtoundertakecostcalcula- Resourceutilizationduringfollow-up
tions.Categoricalvariablesweredescribedbynumberandfrequencyof
Duringthewholestudyperiod,HMONpatientshadsignificantlyless
thenon-missingdataandcomparedbetweenarmsusingtheFisher`sexact
scheduledin-officeFUvisitsthanHMOFFpatients(Table2).Despite
test.ContinuousvariablessuchasnumberofFUvisitswerenotnormally
distributedandwerethereforecomparedbetweenarmsusingthenon- asignificantlyhighernumberofunscheduledin-officeFUvisitsinthe
parametricMann–WhitneyUtest.Alltestswereinterpretedtwo-sided, HMONgroup,thetotalnumberofFUvisitswasstillsignificantly
ata5%levelofsignificance. lower with HM ON (3.79+1.67 vs. 5.53+2.32, P,0.001). On
162 H.Heidbucheletal.
Table1 Patientcharacteristicsandstudyexecution
Variable Allpatients(n5303) HMOFF(n5144) HMON(n5159)
...............................................................................................................................................................................
Meanage+SD,years 62.4+13.1 62.9+12.3 62.0+13.9
Malegender,% 80.5 83.3 78.0
MeanLVEF+SD,% 39.4+15.1 39.5+15.6 39.2+14.8
MeanQRSduration+SD,ms 112+27 112+28 111+26
Primary/secondaryprophylacticindication,%* 50.8/49.2 44.1/55.9 57.0/43.0
Single-/dual-chamberICD,% 60.7/39.3 61.1/38.9 60.4/39.6
Replacement,n(%) 37(12.2) 16(10.4) 21(13.2)
Medication,%
Beta-blocker 81.8 83.3 80.5
ACE-inhibitororARB 65.7 71.5 60.4
Diuretic 53.1 56.9 49.7
Anti-arrhythmic 23.1 25.7 20.8
...............................................................................................................................................................................
MeanFUtime,months+SD 21.8+6.3 21.2+7.0 22.4+5.5
Terminationbefore24monthsvisit,n(%) 61(20.1) 33(22.9) 28(17.6)
Irregularearlytermination(seenote)a,n(%) 14(4.6) 5(3.5) 9(5.7)
Withdrawalofconsent(%) 6(2.0) 5(3.5) 1(0.6)
Death,n(%) 21(6.9) 9(6.3) 12(7.5)
Investigatorsdecision,n(%) 4(1.3) 4(2.8) 0
Deviceswitchedoff/explanted/upgraded,n(%) 9(3.0) 7(4.9) 2(1.3)
Hearttransplantation,n(%) 3(1.0) 2(1.4) 1(0.6)
Other,n(%) 4(1.3) 1(0.7) 3(1.9)
...............................................................................................................................................................................
FUforearlyterminationpatients,months+SD 11.9(8.3) 10.2(7.5) 13.8(9.0)
*P¼0.029(Fisher’sexacttest)fordifferenceinrateofprimaryprophylacticindicationbetweenHMONandHMOFF.Furtherdifferencesbetweengroupswerestatistically
insignificant.ACE,angiotensin-convertingenzyme;ARB,angiotensinreceptorblockers;ICD,implantablecardioverter-defibrillator;LVEF,leftventricularejectionfraction.
aPatientswith‘Irregularearlytermination’didnotterminatethestudyregularlywithafinal24-monthFU.However,foronepatientintheHMOFFgroupandthreepatientsintheHM
ONgroup,data(e.g.HMinformation,AE-reports,etc.)wasavailablebeyond22monthsafterimplantdischarge.
theotherhand,theHMONgrouphadsignificantlymoreFUcontacts difference(E236to54),NS],withoutdifferencesineitherdirect
outsideofFUvisits(i.e.phonecalls)andinternaldiscussionsamong medicalornon-medicalcosts.Fortheaveragetrialpatient,alsothe
staff(Table2).Therewerenosignificantchangesintheutilization FU-related reimbursement was identical, leading to an unaffected
of other healthcare services, although there were numerically netclinicalincomefortheprovider[profitofE408(327–489)vs.
fewercardiovascular hospitalizations and shorter length-of-stayin E400(345–455);rangefordifference(E2104to88),NS].
theHMONpatients(Table2). Fromapayerperspective(Figure3B),therewasasmallalbeitnot
Theaveragetimespentoneachoftheabove-mentionedcontacts statisticallysignificantdecreaseintotalcostsovera2-yearperiod
wasnotsignificantlydifferentforHMONvs.OFFpatients,neitherfor (excludingthecostofthedeviceandofanyremotemonitoringequip-
physicians,nursesnortechnicians(Table2).Figure2showsthecumu- mentorcommunicationcosts).Themaincostdriverforpayersisthe
lativetimespentoneverypatientforallcontactscombined:HMdid numberofhospitalizationdaysforpatients:inlinewithnumerically
notchangethetotaltimeneededforfollow-up,northecumulative fewer hospitalizations and a shorter length-of-hospital stay, there
time for all types of personnel combined: over the study period, wasanumerical (non-significant) reductioninhospitalizationcosts.
176min of staff time per patient were required for HM ON vs. Therewasnodifferenceinthecostsrelatedtonon-providerphysician
178mininHMOFFpatients(NS).Onlyphysiciansspentsignificantly visitsorexaminations.
lesstimeforpatientsinHMON,butthedifferencewassmall(64vs. Multivariabletestingshowedthatthecostforproviderswasonly
73min,P¼0.028). significantlydependentonthecountry(P,0.001),whilefortotal
payer cost only the type of ICD (VVI vs. DDD) had a significant
Costsforfollow-up
impact (P,0.001). Costs were not dependent on primary or
Figure3Ashowsthemonetaryvaluationofthetimeneededbydiffer- secondaryindicationforimplant(Table3).
entproviderpersonnelduringFUandthenon-medicalcosts(mainly Figure4illustratestheheterogeneityamongcountries,withless
overhead): from a provider perspective, the average cost for FU profit for providers in the absence of specific remote FU reim-
during2yearswasnotdifferentfortheHMONandOFFgroups bursement (leftside:Belgium,Netherlands,andSpain)vs.main-
[mean(95%CI):E204(169–238)vs.E213(182–243);rangefor tained or increased profit in case such reimbursement exists
Table2 Resourceuseduring2yearsofimplantablecardiacdefibrillatorfollow-up,andaveragetimeneededforeachofthefollow-upactivities
Activity Averagenumberofservices Averagetimeneeded(min)
Mean(SD) Mean(SD)
Median(IQR) Median(IQR)
.................................................................... .....................................................................................................................
HMOFF(n5144) HMON(n5159) P-value HMOFF(n5144) HMON(n5159) P-value
........................................................ .......................................................
Physician Nurse Technician Physician Nurse Technician
.............................................................................................................................................................................................................................................
TotalFUvisits 5.53(2.32) 3.79(1.67) ,0.001
5.00(2) 3.00(1)
Scheduledvisits 4.92(1.89) 2.84(0.81) ,0.001 13.49(8.84) 10.35(8.98) 6.65(10.40) 14.19(9.28) 11.08(9.51) 6.40(12.46) NS
5.00(2) 3.00(0) 13.80(12.0) 9.11(12.1) 0.00(13.8) 12.88(12.0) 9.42(12.9) 0.00(10.3)
Unscheduled 0.62(1.25) 0.95(1.50) ¼0.005 13.43(12.33) 8.82(10.81) 9.59(13.27) 16.32(11.9) 9.59(11.13) 6.67(12.25) NS
0.00(1) 0.00(1) 12.50(17.0) 5.00(12.5) 0.00(19.5) 13.33(14.0) 7.00(15.0) 0.00(10.0)
.............................................................................................................................................................................................................................................
OtherFUcontacts 1.01(2.64) 1.95(3.29) ,0.001
0.00(0) 1.00(2)
Physician 0.06(0.38) 0.22(0.64) ¼0.003 8.93(4.96) 5.44(3.95) NS
0.00(0) 0.00(0) 10.00(5.0) 4.00(2.2)
Nurse 0.89(2.48) 1.53(2.97) 0.002 5.31(3.33) 5.91(5.72) NS
0.00(0) 0.00(2) 4.40(3.3) 4.20(3.9)
Technician 0.08(0.31) 0.23(0.89) NS 16.28(11.9) 12.04(11.93) NS
0.00(0) 0.00(0) 13.00(11.5) 10.75(11.8)
.............................................................................................................................................................................................................................................
Remotemonitoring 0.06(0.31) 11.02(15.28) ,0.001
services 0.00(0) 6.00(15)
Physician 0.01(0.12)* 1.86(4.54) ,0.001 0 2.87(3.21)
0.00(0) 0.00(1) 0(0) 2.00(17)
Nurse 0.04(0.29)* 7.74(12.82) ,0.001 0 3.40(2.30)
0.00(0) 2.00(12) 2.13(0) 2.85(12)
Technician 0.01(0.08)* 1.47(6.78) ,0.001 0 2.86(3.49)
0.00(0) 0.00(0) 0(0) 1(16)
.............................................................................................................................................................................................................................................
Internaldiscussions 1.28(2.92) 1.84(4.20) 0.03
0.00(2) 1.00(2)
Physician 4.38(3.84) 5.31(4.57) NS
3.00(4.7) 4.03(3.8)
Nurse 4.80(4.26) 4.14(3.28) NS
3.38(4.1) 3.12(3.3)
Technician 4.34(4.11) 4.96(5.55) NS
3.04(5.1) 3.00(4.9)
.............................................................................................................................................................................................................................................
Continued
EuroEco,HealthEconomicTrialonhomemonitoring
163
(rightside:GermanyandUK).Nevertheless,theoverallcostsfrom
thepayerperspectivewerenumericallylowerincountrieswithout
reimbursement, and were similar in those with reimbursement
(Figure5).
Othersecondaryend-points
TherewerenodifferencesbetweenHMONandOFFinanyofthe
SF-36patient-reportedqualityoflifemeasures,notatbaseline,and
notat1yearor2yearsofFU,andtherewerenochangesduring
thecourseofthestudyinanyofthemeasures:PCSatenrolment
was44.7+9.3forHMONvs.45.2+9.7forHMOFF,withrespect-
ivevaluesat1year43.9+11.1vs.45.1+10.2,andat2years44.4+
11.0vs.45.4+10.6;MCSatenrolment48.8+10.6forHMONvs.
46.8+11.3forHMOFF,andat1and2years49.3+10.2vs.48.9+
10.2 and 48.0+11.5 vs. 47.8+10.8, respectively (all inter- and
intragroup comparisons non-significant). In the HM ON group,
32.0%ofin-officeFUvisits(193/603)resultedinaclinicallyrelevant
finding/action(‘actionablevisits’)comparedwith26.8%(213/795)in
theHMOFFgroup(P,0.05).
Discussion
Although remote monitoring technology of cardiac implantable
devicesenteredtheclinicalfield(cid:4)10yearsago,EuroEcoisthefirst
trialestimatingthecostforprovidersinsettingupanorganization
basedonsuchtechnology.PriortrialshaveshownthatsuchFUis
non-inferior clinically from a major events perspective, and even
has clinical advantages like earlier actionability on clinical- or
device-related findings, fewer and shorter hospitalizations, fewer
inappropriate shocks, longer battery longevity, and even lower
mortality.1,6,7,9,10,14 Taken together with data on the existing
reimbursement situation (defining provider income) and on the
costs from a payer perspective, EuroEco also allowed to estimate
theimpactonthenetincomeofphysiciansandhospitals.Thefinancial
impactisanimportantdeterminantforphysiciansandhospitalswhen
consideringadoptionofaremotemonitoring-basedFU.Thefindings
intheoverallEuroEcopopulationshowednochangeinprovidercost
ofHMbasedvs.classicalFU,norontheirnetincome.TheHMON
armincludedsignificantlymorepatientswithaprimaryprophylaxis
indication(whocouldbeexpectedtorequirelessintensiveFUor
havelesscomplications),butmultivariateanalysisdidnotshowasig-
nificantimpactofthisvariableonprovidercosts.Althoughthesample
sizecalculationwasbasedontimeinvestmentfindings,costvaluation
wasnotusedasbasisforthepowercalculations.Theaspectofhet-
erogeneityincostbetweenthecountrieswasunderestimated.This
may have decreased the initially calculated power. Nevertheless,
theveryclosevaluesforbotharmsfortotaltimeinvestmentand
fortheprimaryend-pointmakeitveryunlikelythatahighersample
sizemighthavefounddifferentoverallresults.
Incontrasttotheoveralltrialpopulationresult,thepatternsof
providernetincomeinindividualcountriesareofmostrelevance
when interpreting the study data. In countries that have already
implemented reimbursement for remote monitoring (like the UK
and Germany), provider net income will increase, thus leading to
an incentive to use remote monitoring. It is very plausible that in
other countries (like Belgium, The Netherlands, or Spain in our
deunitnoC
2elbaT
)nim(dedeenemitegarevA
secivresforebmunegarevA
ytivitcA
)DS(naeM
)DS(naeM
)RQI(naideM
)RQI(naideM
.....................................................................................................................
....................................................................
eulav-P
)9515n(NOMH
)4415n(FFOMH
eulav-P
)9515n(NOMH
)4415n(FFOMH
.......................................................
........................................................
naicinhceT
esruN
naicisyhP
naicinhceT
esruN
naicisyhP
.............................................................................................................................................................................................................................................
412.0
)37.8(19.5
)13.8(46.4
stisivnaicisyhprehtO
)7(00.2
)5(00.2
258.0
)52.1(85.0
)95.1(96.0
tneitaptuO
)1(00.0
)1(00.0
snoitanimaxe
UFgniruddetaitini
332.0
)81.1(76.0
)34.1(58.0
snoitazilatipsohVC
)1(00.0
)1(00.0
662.0
)5.51(13.6
)6.81(62.8
yatslatipsohfohtgneL
)5(00.0
)7(00.0
)syad(
.noitaiveddradnats,DS;tnacfiingiston,SN;egnarelitrauq-retni,RQI;pu-wollof,UF;ralucsavoidrac,VC
.)TTI(puorgFFOMHehtnidetnuocerewstcatnocUFetomerrieht,puorgNOehtotFFOehtmorfrevo-dessorcstneitapemosecniSa
164 H.Heidbucheletal.
EuroEco,HealthEconomicTrialonhomemonitoring 165
Figure2 Stafftimespentduring2yearsofimplantablecardiacdefibrillatorfollow-up.Thetimeneededtofollow-uptheaveragepatientfor2years
didnotchangewithHM.Overthestudyperiod,178minofstafftimeperpatientwererequiredforHMOFFvs.176mininHMONpatients.Sig-
nificantchangesareindicatedbyanasterisk,andtheP-valueismentioned.Left:thetimesavedbythereductionofin-clinicfollow-upsisre-directedto
performingremotemonitoring,callpatientsmorefrequentlyanddiscusspatientdatamoreoften.Right:onlyphysiciantimewassignificantlylower
withHMON,albeittoasmallextent.
Figure3 Primaryandmainsecondaryend-points:averagecostsperpatientovertwoyearsoffollow-up.Noneofthesetrialaveragevaluesforall
patientscombinedweresignificantlydifferent.
study),theremaybemoreincentivestomaintainclassicin-officeFUs, Aninterestingobservationisthatthetotalcostfortheinsurance
sincethatistheonlywaytogetreimbursementforFUactivities,costs payerdecreases,albeitnotsignificantly,anddoesnotevenincrease
beingsimilar. in countries that have already implemented remote FU
166 H.Heidbucheletal.
Table3 Multivariableregressionofproviderandtotalpayercostsvs.differentindependentvariables
Dependentvariable Independentvariable Coefficient(SE) P-value
...............................................................................................................................................................................
Providercost HMONvs.OFF 20.119(0.079) 0.13
Age≤medianvs..median 20.041(0.080) 0.61
NYHAclass≤IIvs.≥III 0.039(0.116) 0.74
Singlevs.dualchamberICD 20.142(0.087) 0.10
Primaryvs.secondaryICD 20.012(0.084) 0.89
Country –a ,0.001
...............................................................................................................................................................................
Totalpayercost HMONvs.OFF 20.226(0.326) 0.17
Age≤medianvs..median 20.212(0.157) 0.18
NYHAclass≤IIvs.≥III 20.366(0.237) 0.12
Singlevs.dualchamberICD 20.585(0.176) ,0.001
Primaryvs.secondaryICD 0.217(0.183) 0.24
Country –a 0.011
Basedonageneralizedlinearmodelwithagammadistributionandaloglink.
aThevariable‘country’wasanalysedforwhethertherewasanyrelevantdifferencesintheresultsforthedifferentcountries.Subsequentpairwisecomparisonswereundertaken,
showingthattheprovidercostperpatientforallcountriesdiffersignificantlyfromeachother.
SE,standarderror.
reimbursement,showingthatthereisroomforsuchpropercompen- thesecentresdonotnecessarilyrepresenttheaveragepracticein
sationofproviders.EuroEcoobservednumericallyfewerandshorter eachcountry.Also,theremayhavesomeunderreportingoftheutil-
hospitalizations,findingsthatcorroboratewithsimilarresultsfrom izationdatainthetrial.Incontrasttootherclinicaltrials,inwhicha
otherICDtrialssuchasECOST(withnon-significantlowerhospital pre-specified regimen is guiding data gathering, investigators and
costs) and CONNECT (showing a significantly shorter length of nursesinEuroEcohadtodevelopareflexofdocumentingallcontacts
stay)9,11 as well as from pacemaker trials such as COMPAS and andtheirtimingwhendealingwithstudyICDpatients,oftenunex-
Oedipe.7,19 EuroEco did not make any cost-effectiveness calcula- pectedly(alerts,phonecalls,...).Althoughwedevelopedspecific
tions, since the payer perspective was not the primary one, and toolstofacilitatethiswork,somecontactsmayhavegoneundocu-
sincethetrialwasnotpoweredtodetectsignificantdifferencesin mented.Nevertheless,ourtimemeasurementsfoundhighertime
clinicaloutcomeparameters.AstheSF-36measurementsindicated, consumption for FU in EuroEco compared with some previous
we could also not detect a significant difference in health-related trials. For example, the total nurse+technician time for remote
quality-of-life, although prior trials have shown a high level of FU(i.e.excludingthein-officevisits)documentedinEuroEcowas
patientacceptanceandsatisfaction.3 59minperpatientover2years,whichwouldequalto (cid:4)246min
Inourcostanalysis,wedeliberatelydidnottakeintoaccountany per month for 100 patients followed. Earlier trials estimated this
remotemonitoringequipmentitself,nordidweincludecommunica- cumulative time (cid:4)43, 59,14,22 and 660min,13 a difference which
tioncosts,becausesuchcostscouldbecriticizedasbeingarbitrary mayberelatedtothedifferenttasksincludedintheanalysis.
since mainly based on unilateral estimates by the manufacturer. ThesavinginphysiciantimewasonlymodestinEuroEco(73vs.
Nevertheless,giventheoveralllowercostsforpayerswithremote 64minover2years;P¼0.028)andtotalphysiciantimewashigher
monitoring, EuroEco will allow informed discussions between all than in other trials,13,22 despite a similar significant reduction of
parties(payers,providers,andmanufacturers)tocometobalanced in-officevisits.Thismaybeduetoalearningcurve,wherephysicians
reimbursementscenariosforall.Scientificorganizationsandindustry tendedtodomoreoftheHMworkintheearlyphaseofadoption,
havealreadydevelopedframeworksonhowtoprovideappropriate whilerelayingmoretotrainednursesinalaterphase.EuroEcowas
reimbursement for device telemonitoring, with general principles startedin2008,i.e.shortafterHMtechnologywasadoptedintheclin-
andcountry-specificmeasures.20,21TheEuroEcodatamaycertainly icalfield.Also,ourtrialdidamuchmoredetailedanddiversetime
servetospecifytheserecommendationsfurther. tracking of physician commitments during FU than other studies,
While we are confident about the direction of the findings on including internal discussions, phone calls and unscheduled visits.
income impact of remote monitoring in different countries, we Thiscanalsoexplainwhyothertrialsalsoreportedamuchlower
want to raise caution about the absolute values of the calculated physician-thannurse-time(10–25%)whilebothwerecomparable
costsandreimbursementswhichshouldnotbetakenforgranted. overthefulltrialperiodinourstudy.13,14Nevertheless,ourdataindi-
First,therewasnostatisticalsignificanceinanyofthecostcompari- catethatHMallowsreducingphysiciantimeandshiftingittoother
sonsHMONvs.OFFintheindividualcountryscenarios,whichmay competentstaffmembers,whichisoneoftheprimedriversofhealth-
berelatedtothesmallergroupsasresultofthesplittingofthewhole carereformallovertheworld.Thedisparitybetweennurseandtech-
populationduetoheterogeneityofutilizationdata.Second,costdata niciantime,asseeninEuroEco,mayreflectcountry-baseddifferences
were derived from country-based national databases and tariffs, thatinessencemightnotbefundamental:bothnursesandtechnicians
whichmaynotalwaysbefullyrepresentativeofaspecifichospital’s were specifically qualified personnel for device FU in all centres.
situation. Third, only a few centres per country participated and Hence, the activities performed by a study nurse in one centre
EuroEco,HealthEconomicTrialonhomemonitoring 167
Figure4 Country-dependentvariationsinprovidercostsandincome.Althoughprovidercostsforfollow-uparesimilarforHMONorOFF
patientsinallcountries,thenetincomeimpactofeitherfollow-upstrategyisdependentontheexistingreimbursementprovisionforremote
monitoring-related activities by the provider (physicians, nurses, and technicians): in countries without such provisions (and usually only a
fee-for-serviceforin-personvisits),netincomeoftheprovidersdecreases,whileitincreasesifremotemonitoringreimbursementisavailable
(UKandGermany).
couldberegardedinterchangeablewiththeresponsibilitiesoftechni- Conclusion
ciansinotherpractices/countries.AlsotheEHRAreportonresource
useduringdeviceFUrevealedtheseregionaldifferences.23 ForallthepatientsasawholeintheEuroEcotrial,FU-relatedcosts
ThisEuroEcoreportonlydealswithVVI-andDDD-ICDpatients. forproviderswerenotdifferentforFUbasedonremotemonitoring
Thestudyhasbeenextendedbyalsoincludingheartfailurepatients vs.purelyin-officeFUofVVI-orDDD-ICDpatients,despitereorga-
withacardiacresynchronizationICD(CRT-D),forwhomamore nizedcarewithclearlydifferentutilizationpatterns.Thecostsforthe
complexandtime-intensiveclinicalanddeviceFUcanbeanticipated. payers of healthcare were also statistically similar, although with
Itneedstobeseeninhowfarthehealth-economicresultsreported numerically decreased costs if HM ON, related to numerically
herecanbeextendedtotheCRT-Dpopulation. fewer and shorter hospitalizations. Disparity in the impact on
168 H.Heidbucheletal.
Figure5 Country-dependenttotalhealthcarepayercostsduring2yearsoffollow-up.Evenincountrieswhereremotemonitoringreimburse-
mentisavailable(UKandGermany),totalcostsforhealthcarepayersover2yearsoffollow-updonotincrease.
provider budget among different countries illustrates the need grantsandotherfromBiotronik,otherfromMedtronic,grantsand
for proper reimbursement to ensure effective implementation of other from Stereotaxis, grants and other from Boston Scientific,
remoteFU. during the conduct of the study, grants and other from Biosense
Webster,grantsandotherfromStJudeMedical,grantsandother
Acknowledgements
from Biotronik, other from Medtronik, grants from Stereotaxis,
TheauthorswishtoacknowledgethesupportofCristinaIvanescu, other from Boston Scientific, outside the submitted work. S.L.
KonstantinaSkaltsa,XandraLie,andAnkevanEngen,allofQuintiles reportsgrantsfromBIOTRONIK,duringtheconductofthestudy.
Consulting, a subsidiary of Quintiles Ltd, UK, who contributed A.M. reports grants from Biotronik, during the conduct of the
withtheirstatisticalandhealtheconomicexpertisetothiscompre- study.A.S.isanemployeeofBiotronikSE&CoKG,Berlin,Germany.
hensivedataevaluation.ManythanksalsotoBeateWenzel,Sascha
Mrosk,andThuanTran,alloftheCenterfor ClinicalResearchat Conflictofinterest:nonedeclared.
BIOTRONIKSE&CoKG,Berlin,Germany,fortheircontribution
totheconductofthisstudyandthedataevaluation.
References
Funding
1. VarmaN,EpsteinAE,IrimpenA,SchweikertR,LoveC.Efficacyandsafetyofauto-
ThisworkwassupportedbyanunrestrictedgrantfromBIOTRONIKSE maticremotemonitoringforimplantablecardioverter-defibrillatorfollow-up:the
&CoKG,Berlin,Germany.FundingtopaytheOpenAccesspublication Lumos-TSafelyReducesRoutineOfficeDeviceFollow-up(TRUST)trial.Circulation
chargesforthisarticlewasprovidedbyBiotronik. 2010;122:325–332.
2. HeidbuchelH,LioenP,FoulonS,HuybrechtsW,EctorJ,WillemsR,EctorH.Poten-
tialroleofremotemonitoringforscheduledandunscheduledevaluationsofpatients
Disclosures withanimplantabledefibrillator.Europace2008;10:351–357.
3. RicciRP,MorichelliL,QuartaL,SassiA,PorfiliA,LaudadioMT,GargaroA,SantiniM.
Long-termpatientacceptanceofandsatisfactionwithimplanteddeviceremote
L.A.reportsgrantsfromBiotronik,duringtheconductofthestudy.
monitoring.Europace2010;12:674–679.
P.B.reportsgrantsfromBiotronik,duringtheconductofthestudy 4. SpenckerS,CobanN,KochL,SchirdewanA,MullerD.Potentialroleofhomemon-
andreceivedgrantsfromStJudeandalsograntsfromBostonScien- itoring toreduceinappropriateshocksinimplantablecardioverter-defibrillator
patientsduetoleadfailure.Europace2009;11:483–488.
tific,outsidethesubmittedwork.I.F.-L.reportspersonalfeesfrom
5. RicciRP,MorichelliL,SantiniM.RemotecontrolofimplanteddevicesthroughHome
BOSTON SC, St Jude Medical, and Biotronik, during the conduct Monitoringtechnologyimprovesdetectionandclinicalmanagementofatrialfibril-
ofthestudy.H.H.reportsotherfromBiotronik,grantsandpersonal lation.Europace2009;11:54–61.
6. Al-KhatibSM,PicciniJP,KnightD,StewartM,Clapp-ChanningN,SandersGD.
feesfromBiotronik,grantsfromBoston-Scientific,grantsfromSt.Jude
Remote monitoring of implantable cardioverter defibrillators versus quarterly
Medical,duringtheconductofthestudyandreceivedpersonalfees device interrogations in clinic: results from a randomized pilot clinical trial.
from Pfizer/BMS, Daiicchi-Sankyo, Bayer, Boehringer-Ingelheim, JCardiovascElectrophysiol2010;21:545–550.
7. MaboP,VictorF,BazinP,AhresS,BabutyD,DaCostaA,BinetD,DaubertJC,
Merck,outsidethesubmittedwork.G.H.reportsgrantsandother
InvestigatorsCT.Arandomizedtrialoflong-termremotemonitoringofpacemaker
from Biosense Webster, grants and other from St Jude Medical, recipients(theCOMPAStrial).EurHeartJ2012;33:1105–1111.
EuroEco,HealthEconomicTrialonhomemonitoring 169
8. Guedon-MoreauL,LacroixD,SadoulN,ClementyJ,KouakamC,HermidaJS, 15. HeidbuchelH.Telemonitoringofimplantablecardiacdevices:hurdlestowards
AliotE,BoursierM,BizeauO,KacetS,InvestigatorsEt.Arandomizedstudyof personalisedmedicine.Heart2011;97:931–939.
remotefollow-upof implantable cardioverterdefibrillators: safetyand efficacy 16. VemerP,Rutten-van MolkenMP. Theroadnot taken:transferabilityissues in
reportoftheECOSTtrial.EurHeartJ2013;34:605–614. multinationaltrials.Pharmacoeconomics2013;31:863–876.
9. Crossley GH, Boyle A, Vitense H, Chang Y, Mead RH, Investigators C. The 17. Willke RJ, Glick HA, Polsky D, Schulman K. Estimating country-specific cost-
CONNECT(ClinicalEvaluationofRemoteNotificationtoReduceTimetoClinical effectivenessfrommultinationalclinicaltrials.HealthEcon1998;7:481–493.
Decision)trial:thevalueofwirelessremotemonitoringwithautomaticclinician 18. DrummondM,BarbieriM,CookJ,GlickHA,LisJ,MalikF,ReedSD,RuttenF,
alerts.JAmCollCardiol2011;57:1181–1189. SculpherM,SeverensJ.Transferabilityofeconomicevaluationsacrossjurisdictions:
10. Hindricks G, Taborsky M, Glikson M, Heinrich U, Schumacher B, Katz A, ISPORGoodResearchPracticesTaskForcereport.ValueHealth2009;12:409–418.
Brachmann J, Lewalter T, Goette A, Block M, Kautzner J, Sack S, Husser D, 19. HalimiF,ClementyJ,AttuelP,DessenneX,AmaraW,InvestigatorsOt.Optimized
PiorkowskiC,SogaardP,GroupftI-TS.Benefitofimplant-basedmultiparametertel- post-operativesurveillanceofpermanentpacemakersbyhomemonitoring:the
OEDIPEtrial.Europace2008;10:1392–1399.
emonitoringinpatientswithheartfailure:resultsoftherandomizedIN-TIMEtrial.
20. DubnerS,AuricchioA,SteinbergJS,VardasP,StoneP,BrugadaJ,PiotrowiczR,
Lancet2014;384:583–590.
HayesDL,KirchhofP,BreithardtG,ZarebaW,SchugerC,AktasMK,ChudzikM,
11. Guedon-MoreauL,LacroixD,SadoulN,ClementyJ,KouakamC,HermidaJS,
MittalS,VarmaN.ISHNE/EHRAexpertconsensusonremotemonitoringofcardio-
AliotE,KacetS,onbehalfoftheEtI.Costsofremotemonitoringvs.ambulatory
vascularimplantableelectronicdevices(CIEDs).Europace2012;14:278–293.
follow-ups of implanted cardioverter defibrillators in the randomized ECOST
21. PricewaterhouseCoopers.MovingtowardsgoodpracticeinthereimbursementofCIED
study.Europace2014;16:1181–1188.
telemonitoring.AstudyconductedinfiveEuropeancountries:Germany,Italy,Spain,
12. RicciRP,MorichelliL,SantiniM.Homemonitoringremotecontrolofpacemakerand
the Netherlands and the UK. http://www.eucomed.org/uploads/Modules/
implantablecardioverterdefibrillatorpatientsinclinicalpractice:impactonmedical
Publications/whitepaper_reimbursementciedtelemonitoring.pdf2012.
managementandhealth-careresourceutilization.Europace2008;10:164–170.
22. RicciRP,MorichelliL,D’OnofrioA,CaloL,VaccariD,ZanottoG,CurnisA,BujaG,
13. VogtmannT,StillerS,MarekA,KespohlS,GomerM,KuhlkampV,ZachG,LoscherS, RovaiN,GargaroA.Manpowerandoutpatientclinicworkloadforremotemonitor-
BaumannG.Workloadandusefulnessofdaily,centralizedhomemonitoringfor ingofpatientswithcardiacimplantableelectronicdevices:DatafromtheHome-
patients treated with CIEDs: results of the MoniC (Model Project Monitor GuideRegistry.JCardiovascElectrophysiol2014;doi:10.1111/jce.12482.
Centre)prospectivemulticentrestudy.Europace2013;15:219–226. 23. Boriani G, Auricchio A, Klersy C, Kirchhof P, Brugada J, Morgan J, Vardas P,
14. RicciRP,MorichelliL,D’OnofrioA,CaloL,VaccariD,ZanottoG,CurnisA,BujaG, European Heart Rhythm A, Eucomed. Healthcare personnel resource burden
RovaiN,GargaroA.EffectivenessofremotemonitoringofCIEDsindetectionand relatedtoin-clinicfollow-upofcardiovascularimplantableelectronicdevices:a
treatmentofclinicalanddevice-relatedcardiovasculareventsindailypractice:the EuropeanHeartRhythmAssociationandEucomedJointSurvey.Europace2011;
HomeGuideRegistry.Europace2013;15:970–977. 13:1166–1173.
